Aragen expands collaboration with MSD

Hyderabad: Aragen Life Sciences (Aragen), a Hyderabad-based contract research and development organisation on Wednesday announced the expansion of its collaboration with MSD (tradename of Merck & Co, Inc, Rahway, NJ, USA) to provide discovery services and solutions supporting MSD's global research and development efforts.

"We look forward to continuing work with MSD researchers to advance its pipeline of therapeutic candidates," said Manni Kantipudi, CEO, Aragen. "At Aragen, our team believes that in every molecule is the possibility for better health. By treating every project with urgency and focus, we look to discover and develop medicines for our collaborators that make a positive impact on patients," the CEO added.

Dr Sudhir Kumar Singh, COO of Aragenfurther informed, "On behalf of all Aragenites, I want to thank MSD for their trust and confidence in us and their decision to expand on the collaboration. Over the past several years, we have worked diligently at building a world-class scientific team, equipping them with state-of-the-art infrastructure, and inculcating a culture of customer-centricity."

Aragen Life Sciences is a R&D and manufacturing solutions provider to the global life sciences industries. The company offers a range of solutions across the drug development continuum to advance small and large molecule programs. With more than 20 years of experience, the company operates through a global network of six sites with a team of over 3800 employees and 450 PhDs.

Through their expertise and experience over 450 customers have been enable, including seven of the top 10 pharma companies globally, in advancing their research programs from early discovery through development and commercialization. Aragen official said its innovative mindset, infrastructure, flexible business models, a clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally.